{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:09:46Z","timestamp":1788016186863,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["BHC-RD-SOP-038"],"award-info":[{"award-number":["BHC-RD-SOP-038"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010318","name":"Landelijke Stichting voor Blinden en Slechtzienden","doi-asserted-by":"publisher","award":["Uitzicht-2021-32"],"award-info":[{"award-number":["Uitzicht-2021-32"]}],"id":[{"id":"10.13039\/501100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010302","name":"Algemene Nederlandse Vereniging ter voorkoming van Blindheid","doi-asserted-by":"publisher","award":["Uitzicht-2021-32"],"award-info":[{"award-number":["Uitzicht-2021-32"]}],"id":[{"id":"10.13039\/501100010302","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stichting Beheer Het Schild via Steunfonds Uitzicht","award":["Uitzicht-2021-32"],"award-info":[{"award-number":["Uitzicht-2021-32"]}]},{"DOI":"10.13039\/501100010321","name":"Oogfonds","doi-asserted-by":"publisher","award":["Uitzicht-2021-32"],"award-info":[{"award-number":["Uitzicht-2021-32"]}],"id":[{"id":"10.13039\/501100010321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>To investigate the potential effect of anti-VEGF treatment on choroidal thickness (CT) in unilateral neovascular age-related macular degeneration (AMD) patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>This is a cross-sectional study where patients were included as part of an ongoing prospective study which included patients with unilateral neovascular (n) AMD. The fellow-eye served as control. All patients had spectral-domain optical coherence tomography (SD-OCT) with enhanced depth imaging (EDI) done at every visit. CT was measured independently by two graders at five locations: subfoveal, 1500 micron temporal and nasal, 3000 micron temporal and nasal. The average of the measurements was used after statistical verification of their accuracy. CT differences were initially analysed via a paired T-test and later via multiple linear regression. Variables such as number of injections were studied and presence of geographic atrophy (GA) in fellow-eyes was evaluated via SD-OCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 112 patients met the inclusion criteria (Female 67%). The median (IQR) years of treatment was 2.6 (4.1). The subfoveal choroidal thickness (SFCT) in the neovascular (NV) eye appeared thinner in the NNV eye initially (-11.0\u00a0\u03bcm difference between NV and NNV SFCT (CI -23.4 to 1.3). However, after age-adjustment this trend disappeared (CI -29.8 to 4.6). In fact, apart from age (CI -6.2 to -0.1)), no other variable including number of anti-VEGF injections (CI -1.5 to 1.4) predicted SFCT. Presence of GA in fellow eyes did not influence the SFCT compared to non-GA fellow eyes, difference (CI -59.7 to 46.6).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study shows no statistically significant CT difference in NV versus NNV eyes. There was no relationship between number of injections and CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Messages<\/jats:title>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>What is known<\/jats:italic>\n              <\/jats:bold>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Intravitreal injection with anti-vascular endothelial growth factors (anti-VEGF) is the mainstay treatment for exudation secondary to neovascular AMD. One quarter of anti-VEGF treated neovascular AMD patients will develop signs of macular atrophy within 2 years, possibly related to anti-VEGF treatment.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>What this study adds<\/jats:italic>\n              <\/jats:bold>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>A hypothesized mechanism for atrophy induction is the effect of anti-VEGF on choroidal thickness. In this cross-sectional study, we found a non-significant 11 micron difference between anti-VEGF treated eyes and non-treated eyes in long-term follow-up neovascular AMD patients. A relationship between choroidal thinning and the number of anti-VEGF injections was furthermore not shown.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>How this study might affect research, practice or policy<\/jats:italic>\n              <\/jats:bold>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>There is no significant choroidal thickness difference between anti-VEGF treated and non-treated long-term follow-up neovascular AMD. We therefore suggest that atrophy induction through choroidal thinning secondary to anti-VEGF injections is of limited concern.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00417-025-06751-7","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T06:11:46Z","timestamp":1741414306000},"page":"1543-1551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparable choroidal thickness between treated eyes and untreated fellow-eyes in patients with unilateral neovascular AMD: a paired-eyes comparative study"],"prefix":"10.1007","volume":"263","author":[{"given":"Francesco","family":"Cinque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke M","family":"van den Tillaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Yzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"de Breuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J","family":"Heesterbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel B","family":"Hoyng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-4625","authenticated-orcid":false,"given":"Yara TE","family":"Lechanteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"12","key":"6751_CR1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP et al (2017) Prevalence of age-related Macular Degeneration in Europe: the past and the future. Ophthalmology 124(12):1753\u20131763. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.035","journal-title":"Ophthalmology"},{"issue":"9","key":"6751_CR2","doi-asserted-by":"publisher","first-page":"Oct14","DOI":"10.1167\/iovs.16-19969","volume":"57","author":"PJ Rosenfeld","year":"2016","unstructured":"Rosenfeld PJ (2016) Optical coherence tomography and the development of Antiangiogenic therapies in Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 57(9):Oct14\u201326. https:\/\/doi.org\/10.1167\/iovs.16-19969","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"6751_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","volume":"6","author":"S Aslanis","year":"2022","unstructured":"Aslanis S, Amr\u00e9n U, Lindberg C, Epstein D (2022) Recurrent neovascular age-related Macular Degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen. Ophthalmol Retina 6(1):15\u201320. https:\/\/doi.org\/10.1016\/j.oret.2021.03.010","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"6751_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000520171","volume":"245","author":"A Foss","year":"2022","unstructured":"Foss A, Rotsos T, Empeslidis T, Chong V (2022) Development of Macular Atrophy in patients with wet age-related Macular Degeneration receiving Anti-VEGF treatment. Ophthalmologica 245(3):204\u2013217. https:\/\/doi.org\/10.1159\/000520171","journal-title":"Ophthalmologica"},{"issue":"5","key":"6751_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaophthalmol.2013.692","volume":"131","author":"L Branchini","year":"2013","unstructured":"Branchini L, Regatieri C, Adhi M, Flores-Moreno I, Manjunath V, Fujimoto JG, Duker JS (2013) Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age-related macular degeneration using spectral-domain optical coherence tomography. JAMA Ophthalmol 131(5):693\u2013694. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.692","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"6751_CR6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2012) Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119(8):1621\u20131627. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.022","journal-title":"Ophthalmology"},{"issue":"1","key":"6751_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","volume":"124","author":"JE Grunwald","year":"2017","unstructured":"Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ et al (2017) Incidence and growth of Geographic Atrophy during 5 years of comparison of age-related Macular Degeneration treatments trials. Ophthalmology 124(1):97\u2013104. https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.012","journal-title":"Ophthalmology"},{"issue":"78","key":"6751_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19780","volume":"19","author":"U Chakravarthy","year":"2015","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes S, Lotery AJ, Dakin HA et al (2015) A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to inhibit VEGF in Age-related choroidal neovascularisation (IVAN). Health Technol Assess 19(78):1\u2013298. https:\/\/doi.org\/10.3310\/hta19780","journal-title":"Health Technol Assess"},{"issue":"4","key":"6751_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R et al (2015) Short-term changes in Choroidal Thickness after Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. Am J Ophthalmol 159(4):627\u201333e1. https:\/\/doi.org\/10.1016\/j.ajo.2014.12.025","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"6751_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T et al (2016) Subfoveal Choroidal thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: twelve-Month results. Ophthalmology 123(3):617\u2013624. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.039","journal-title":"Ophthalmology"},{"issue":"4","key":"6751_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00417-020-04957-5","volume":"259","author":"M Pellegrini","year":"2021","unstructured":"Pellegrini M, Bernabei F, Mercanti A, Sebastiani S, Peiretti E, Iovino C et al (2021) Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 259(4):911\u2013918. https:\/\/doi.org\/10.1007\/s00417-020-04957-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"6751_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40123-019-00221-0","volume":"9","author":"G Cennamo","year":"2020","unstructured":"Cennamo G, Montorio D, D\u2019Alessandro A, Napolitano P, D\u2019Andrea L, Tranfa F (2020) Prospective study of Vessel density by Optical Coherence Tomography Angiography after Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration. Ophthalmol Ther 9(1):77\u201385. https:\/\/doi.org\/10.1007\/s40123-019-00221-0","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"6751_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/02713683.2017.1405045","volume":"43","author":"M Gharbiya","year":"2018","unstructured":"Gharbiya M, Giustolisi R, Marchiori J, Bruscolini A, Mallone F, Fameli V et al (2018) Comparison of short-term Choroidal Thickness and Retinal Morphological changes after Intravitreal Anti-VEGF therapy with Ranibizumab or Aflibercept in Treatment-naive eyes. Curr Eye Res 43(3):391\u2013396. https:\/\/doi.org\/10.1080\/02713683.2017.1405045","journal-title":"Curr Eye Res"},{"issue":"4","key":"6751_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000488254","volume":"240","author":"TCM Kanadani","year":"2018","unstructured":"Kanadani TCM, Veloso CE, Nehemy MB (2018) Subfoveal Choroidal thickness in eyes with Neovascular Age-Related Macular Degeneration Treated with anti-vascular endothelial growth factor agents. Ophthalmologica 240(4):200\u2013207. https:\/\/doi.org\/10.1159\/000488254","journal-title":"Ophthalmologica"},{"issue":"6","key":"6751_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/bjophthalmol-2016-309281","volume":"101","author":"A Govetto","year":"2017","unstructured":"Govetto A, Sarraf D, Figueroa MS, Pierro L, Ippolito M, Risser G et al (2017) Choroidal thickness in non-neovascular versus neovascular age-related macular degeneration: a fellow eye comparative study. Br J Ophthalmol 101(6):764\u2013769. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309281","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"6751_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.oret.2022.11.002","volume":"7","author":"G Staurenghi","year":"2023","unstructured":"Staurenghi G, Cozzi M, Sadda S, Hill L, Gune S (2023) Characteristics that correlate with Macular Atrophy in Ranibizumab-treated patients with neovascular age-related Macular Degeneration. Ophthalmol Retina 7(4):300\u2013306. https:\/\/doi.org\/10.1016\/j.oret.2022.11.002","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"6751_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12886-020-01766-6","volume":"21","author":"J Siedlecki","year":"2021","unstructured":"Siedlecki J, Koch C, Schworm B, Liegl R, Kreutzer T, Kortuem KU et al (2021) Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment. BMC Ophthalmol 21(1):4. https:\/\/doi.org\/10.1186\/s12886-020-01766-6","journal-title":"BMC Ophthalmol"},{"key":"6751_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ajo.2016.06.023","volume":"169","author":"VS Vuong","year":"2016","unstructured":"Vuong VS, Moisseiev E, Cunefare D, Farsiu S, Moshiri A, Yiu G (2016) Repeatability of Choroidal thickness measurements on enhanced depth imaging Optical Coherence Tomography using different posterior boundaries. Am J Ophthalmol 169:104\u2013112. https:\/\/doi.org\/10.1016\/j.ajo.2016.06.023","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"6751_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC et al (2018) Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: classification of Atrophy Report 3. Ophthalmology 125(4):537\u2013548. https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.028","journal-title":"Ophthalmology"},{"issue":"5","key":"6751_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1557\/mrs2010.571","volume":"35","author":"M Diez-Silva","year":"2010","unstructured":"Diez-Silva M, Dao M, Han J, Lim CT, Suresh S (2010) Shape and Biomechanical Characteristics of Human Red Blood Cells in Health and Disease. MRS Bull 35(5):382\u2013388. https:\/\/doi.org\/10.1557\/mrs2010.571","journal-title":"MRS Bull"},{"issue":"12","key":"6751_CR21","doi-asserted-by":"publisher","first-page":"e0144156","DOI":"10.1371\/journal.pone.0144156","volume":"10","author":"Y Wakatsuki","year":"2015","unstructured":"Wakatsuki Y, Shinojima A, Kawamura A, Yuzawa M (2015) Correlation of Aging and Segmental Choroidal Thickness Measurement using swept source optical coherence tomography in healthy eyes. PLoS ONE 10(12):e0144156. https:\/\/doi.org\/10.1371\/journal.pone.0144156","journal-title":"PLoS ONE"},{"issue":"6","key":"6751_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.oret.2020.09.001","volume":"5","author":"M Sasaki","year":"2021","unstructured":"Sasaki M, Ito Y, Yamasaki T, Yanagi Y, Gemmy Cheung CM, Motomura K et al (2021) Association of Choroidal Thickness with Intermediate Age-Related Macular Degeneration in a Japanese Population. Ophthalmol Retina 5(6):528\u2013535. https:\/\/doi.org\/10.1016\/j.oret.2020.09.001","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"6751_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1167\/iovs.14-14933","volume":"56","author":"M Lindner","year":"2015","unstructured":"Lindner M, Bezatis A, Czauderna J, Becker E, Brinkmann CK, Schmitz-Valckenberg S et al (2015) Choroidal thickness in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 56(2):875\u2013882. https:\/\/doi.org\/10.1167\/iovs.14-14933","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"6751_CR24","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1167\/iovs.18-23960","volume":"59","author":"A Invernizzi","year":"2018","unstructured":"Invernizzi A, Benatti E, Cozzi M, Erba S, Vaishnavi S, Vupparaboina KK et al (2018) Choroidal Structural Changes Correlate with Neovascular Activity in Neovascular Age Related Macular Degeneration. Invest Ophthalmol Vis Sci 59(10):3836\u20133841. https:\/\/doi.org\/10.1167\/iovs.18-23960","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"6751_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/iae.0000000000002845","volume":"41","author":"JY Park","year":"2021","unstructured":"Park JY, Kang MJ, Kim BG, Chung KH, Sim HE, Lee SW, TOPOGRAPHIC CHANGES IN CHOROIDAL THICKNESS IN AGE-RELATED MACULAR DEGENERATION DURING THE DEVELOPMENT OF ACTIVE CHOROIDAL NEOVASCULARIZATION et al (2021) Retina 41(2):409\u2013422. https:\/\/doi.org\/10.1097\/iae.0000000000002845","journal-title":"Retina"},{"issue":"8","key":"6751_CR26","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1111\/aos.14173","volume":"97","author":"SG Karst","year":"2019","unstructured":"Karst SG, Schuster M, Mitsch C, Meyer EL, Kundi M, Scholda C, Schmidt-Erfurth UM (2019) Atrophy of the central neuroretina in patients treated for diabetic macular edema. Acta Ophthalmol 97(8):e1054\u2013e61. https:\/\/doi.org\/10.1111\/aos.14173","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"6751_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/bjophthalmol-2018-312625","volume":"103","author":"JB Kumar","year":"2019","unstructured":"Kumar JB, Wai KM, Ehlers JP, Singh RP, Rachitskaya AV (2019) Subfoveal choroidal thickness as a prognostic factor in exudative age-related macular degeneration. Br J Ophthalmol 103(7):918\u2013921. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312625","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"6751_CR28","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1007\/s12325-022-02129-x","volume":"39","author":"AM Minnella","year":"2022","unstructured":"Minnella AM, Centini C, Gambini G, Savastano MC, Pagliei V, Falsini B et al (2022) Choroidal Thickness Changes after Intravitreal Aflibercept injections in Treatment-Na\u00efve Neovascular AMD. Adv Therapy 39(7):3248\u20133261. https:\/\/doi.org\/10.1007\/s12325-022-02129-x","journal-title":"Adv Therapy"},{"issue":"1","key":"6751_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1167\/iovs.11-8782","volume":"53","author":"CS Tan","year":"2012","unstructured":"Tan CS, Ouyang Y, Ruiz H, Sadda SR (2012) Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 53(1):261\u2013266. https:\/\/doi.org\/10.1167\/iovs.11-8782","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"6751_CR30","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1167\/iovs.17-21598","volume":"58","author":"X Zhang","year":"2017","unstructured":"Zhang X, Cole E, Pillar A, Lane M, Waheed N, Adhi M et al (2017) The effect of change in intraocular pressure on Choroidal structure in glaucomatous eyes. Invest Ophthalmol Vis Sci 58(7):3278\u20133285. https:\/\/doi.org\/10.1167\/iovs.17-21598","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"6751_CR31","doi-asserted-by":"publisher","first-page":"e0240357","DOI":"10.1371\/journal.pone.0240357","volume":"15","author":"M Sato","year":"2020","unstructured":"Sato M, Minami S, Nagai N, Suzuki M, Kurihara T, Shinojima A et al (2020) Association between axial length and choroidal thickness in early age-related macular degeneration. PLoS ONE 15(10):e0240357. https:\/\/doi.org\/10.1371\/journal.pone.0240357","journal-title":"PLoS ONE"},{"issue":"6","key":"6751_CR32","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1111\/bcp.15237","volume":"88","author":"SC Yeung","year":"2022","unstructured":"Yeung SC, Park JY, Park D, You Y, Yan P (2022) The effect of systemic and topical ophthalmic medications on choroidal thickness: a review. Br J Clin Pharmacol 88(6):2673\u20132685. https:\/\/doi.org\/10.1111\/bcp.15237","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"6751_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/iovs.62.3.27","volume":"62","author":"D Nagasato","year":"2021","unstructured":"Nagasato D, Mitamura Y, Egawa M, Murao F, Nagasawa T, Komori N et al (2021) Changes in Choroidal Component ratio and circulation after Coffee Intake in healthy subjects. Investig Ophthalmol Vis Sci 62(3):27. https:\/\/doi.org\/10.1167\/iovs.62.3.27","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"13","key":"6751_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1167\/iovs.64.13.16","volume":"64","author":"M Shen","year":"2023","unstructured":"Shen M, Zhou H, Lu J, Li J, Jiang X, Trivizki O et al (2023) Choroidal changes after Anti-VEGF therapy in AMD eyes with different types of Macular Neovascularization using swept-source OCT angiography. Investig Ophthalmol Vis Sci 64(13):16. https:\/\/doi.org\/10.1167\/iovs.64.13.16","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"6751_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/tvst.8.3.5","volume":"8","author":"H Giannakaki-Zimmermann","year":"2019","unstructured":"Giannakaki-Zimmermann H, Huf W, Schaal KB, Sch\u00fcrch K, Dysli C, Dysli M et al (2019) Comparison of Choroidal thickness measurements using Spectral Domain Optical Coherence Tomography in six different settings and with customized Automated Segmentation Software. Translational Vis Sci Technol 8(3):5. https:\/\/doi.org\/10.1167\/tvst.8.3.5","journal-title":"Translational Vis Sci Technol"},{"issue":"7","key":"6751_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.oret.2020.02.016","volume":"4","author":"R Laiginhas","year":"2020","unstructured":"Laiginhas R, Yang J, Rosenfeld PJ, Falc\u00e3o M (2020) Nonexudative Macular Neovascularization - A systematic review of Prevalence, Natural History, and recent insights from OCT angiography. Ophthalmol Retina 4(7):651\u2013661. https:\/\/doi.org\/10.1016\/j.oret.2020.02.016","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"6751_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.63.9.13","volume":"63","author":"N Harada","year":"2022","unstructured":"Harada N, Nagai N, Mushiga Y, Ozawa Y (2022) Choriocapillaris Flow Imbalance in fellow eyes in age-related Macular Degeneration. Investig Ophthalmol Vis Sci 63(9):13. https:\/\/doi.org\/10.1167\/iovs.63.9.13","journal-title":"Investig Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06751-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06751-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06751-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:59:56Z","timestamp":1751968796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06751-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6751"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06751-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance of ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Medisch-Ethische Commissie Oost-Nederland\u00a0 and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}